Skip to contentR
Relay Therapeutics, Inc.
R
RLAYRelay Therapeutics, Inc. Q1 2023 · 10-Q
Revenue$226.00K$226.00K−46.1% vs Q1 2022 Net Income-$94.24M-$94.24MN/M vs Q1 2022 EPS Diluted-$0.78-$0.78N/M vs Q1 2022 Operating Income-$101,177,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Relay Therapeutics, Inc. · CIK 1812364 · Engraved from SEC EDGAR
Free Cash Flowderived-$69,045,000N/M Margins · derivedOperating margin-44768.6%−29799.4 pt vs Q1 2022
Net margin-41698.7%−26890.6 pt vs Q1 2022
ended Mar 31, 2023 · filed May 4, 2023 · 34 d after period end